All tumor samples were further divided into two cohorts, according to whether the patients had received EGFR‐TKIs or not: cohort 1: TKI‐naive samples from patients who had never received EGFR‐TKIs; and cohort 2: TKI‐relapsed samples from patients who had received reversible EGFR‐TKIs (gefitinib, icotinib, or erlotinib) and acquired resistance. The gene discussed is EGFR; the disease is neoplasm.